Search results
Results from the WOW.Com Content Network
The FDA granted the approval of Inmazeb to Regeneron Pharmaceuticals with an indication for the treatment of infection caused by Zaire ebolavirus in October 2020. [2] [6] The drug has also received orphan drug designation from the European Medicines Agency. [23]
Sacituzumab govitecan was approved for medical use in the United States in April 2020, [12] [13] [15] and in the European Union in November 2021. [10] The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) consider it to be a first-in-class medication. [16] [17]
Ripretinib was approved for medical use in the United States in May 2020, [3] [4] in Australia in July 2020, [1] and in the European Union in November 2021. [5] Ripretinib is the first new drug specifically approved in the United States as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST).
The medication was first used in Europe in 2020 and was later approved by the FDA in 2023. Sales in the US of Librela began in May of 2023. ... (CVM) approves more than 40 new drugs each year.
Remdesivir is the first treatment for COVID‑19 to be approved by the US Food and Drug Administration (FDA). [63] The approval by the FDA does not include the entire population that had been authorized to use remdesivir under an Emergency Use Authorization (EUA) originally issued in May 2020. [63]
In March 2020, it was approved for use in the United States to treat chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). [6] It is the first treatment for this group of fibrosing lung diseases that worsen over time that was approved by the U.S. Food and Drug Administration (FDA). [6]
In February 2020, bempedoic acid was approved for use in the United States both as a standalone drug (brand name Nexletol) [5] [17] [18] [19] and in a fixed-dose combination with ezetimibe (brand name Nexlizet). [20] The U.S. Food and Drug Administration (FDA) granted the approval of Nexletol to Esperion Therapeutics. [2] [5]
In April 2020, the U.S. Food and Drug Administration (FDA) approved tucatinib in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of adults with advanced forms of HER2-positive breast cancer that can't be removed with surgery, or has spread to other parts of the body, including the brain, and who have received one ...